1WU A, LEE C C, JOHNSON M, et al. A new power law for determination of total 125I seed activity for ul trasound-guided protate implants clinical evauations [J]. Int J Radiat Oncol Biol Phys, 2000, 47: 1397- 1403.
2LI Z. An algorithm for automatic, computed-tomo- graphy-based source localization after prostate implant [J]. Med Phys, 2001,28: 1410-1415.
3XIE D Y, ZHANG Z C, LUO X Y. Permanent inter- stitial implantation of 125I seeds for 7 cases of malig- nant tumors[J].cad J Sec Mil Med Univ, 2000,21: 174-176.
4MARTINEZ-MONGE R, NAG S, N1ERODA C A, et al. Iodine-125 brachytherapy in the treatment of color-ectal adenocarcinoma metastatic to the liver[J].Canc- er, 1999,85 : 1218-1225.
5ZELEFSKY M J. Intraoperative conformal optimizaton for transperineal prostate implantaton using magnetic resonance spectroscopic imaging[J]. Cancer J, 2000, 6 : 249-255.
6NATH R, MEIGOONI A S. A comparison of solid phantoms with water for dosimetry of 1-125 and Ir-192 brachytherapy sources[J]. Med Phys, 1990,17 : 1032- 1040.
7LING C C. Permanent implants using Au-198, Pd-103 and 1-125: Radiobiological Considerations based on the linear quadratic model[J]. Int Radiat Oncol Biol Phys, 1992,23:81-87.
8NATH R, MEIGOONI A S, MUENCH P, et al . Anisotropy functions for Pd-103, 1-125, and Ir-192 in- terstitial brachytherapy sources[J]. Med Phys, 1993, 20: 1465-1473.
9WILLIAMSON J F, QUITERO F J. Theortical evalu- ation of dose distribution about models 6711 and 6702 1-125 seeds[J]. Med Phys, 1988,15:891-897.
